Baloxavir Marboxil: A New Antiviral for Acute Influenza

S. Selvanayagam, Amy Kang, David R Ha
{"title":"Baloxavir Marboxil: A New Antiviral for Acute Influenza","authors":"S. Selvanayagam, Amy Kang, David R Ha","doi":"10.37901/jcphp19-00004","DOIUrl":null,"url":null,"abstract":"Baloxavir is a newly approved, single-dose, oral influenza antiviral indicated for acute uncomplicated influenza in patients 12 years and older if symptomatic for less than 48 hours. The purpose of this article is to review currently available literature on the mechanism of action, pharmacokinetics, safety, and clinical and virologic efficacy of baloxavir. Its novel mechanism of action prevents influenza replication by targeting the viral cap-dependent endonuclease enzyme. In clinical trials baloxavir was shown to be superior to placebo and comparable to oseltamivir with regard to time to alleviation of symptoms and viral titer reduction and was well tolerated with minimal adverse effects. Baloxavir is a viable treatment option for acute uncomplicated influenza in certain age groups.","PeriodicalId":15502,"journal":{"name":"Journal of Contemporary Pharmacy Practice","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Contemporary Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37901/jcphp19-00004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Baloxavir is a newly approved, single-dose, oral influenza antiviral indicated for acute uncomplicated influenza in patients 12 years and older if symptomatic for less than 48 hours. The purpose of this article is to review currently available literature on the mechanism of action, pharmacokinetics, safety, and clinical and virologic efficacy of baloxavir. Its novel mechanism of action prevents influenza replication by targeting the viral cap-dependent endonuclease enzyme. In clinical trials baloxavir was shown to be superior to placebo and comparable to oseltamivir with regard to time to alleviation of symptoms and viral titer reduction and was well tolerated with minimal adverse effects. Baloxavir is a viable treatment option for acute uncomplicated influenza in certain age groups.
巴洛沙韦-马博西:一种治疗急性流感的新型抗病毒药物
巴洛西韦是一种新批准的单剂量口服流感抗病毒药物,适用于12岁及以上的急性无并发症流感患者,如果症状持续时间少于48小时。本文的目的是综述目前关于巴洛西韦作用机制、药代动力学、安全性以及临床和病毒学疗效的文献。它的新作用机制通过靶向病毒帽依赖性核酸内切酶来阻止流感复制。在临床试验中,巴洛西韦被证明优于安慰剂,在缓解症状和降低病毒滴度方面与奥司他韦相当,耐受性良好,不良反应最小。对于某些年龄组的急性无并发症流感,巴洛沙韦是一种可行的治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信